BuChE-IN-20 

BuChE-IN-20 is a selective butyrylcholinesterase (hBuChE) inhibitor (IC₅₀ = 0.13 μM) with BBB permeability. BuChE-IN-20 is a L-Tryptophan derivative. BuChE-IN-20 possesses neuroprotective properties by inhibiting the production of nitric oxide (NO) and lowering the levels of ROS. BuChE-IN-20 is proficient in inhibiting the self-aggregation of amyloid-beta (Aβ) peptides. BuChE-IN-20 can be used in research for Alzheimer’s disease^[1].

BuChE-IN-20 (Compound 4d-13) (5 μM, 10 min) shows selectivity for BuChE through enzymatic activity assays of hAChE and hBuChE^[1].
BuChE-IN-20 (20 μM, 48 h) prevents the aggregation and deposition of Aβ_1-42, thereby exerting neuroprotective effects by inhibiting the formation of toxic amyloid plaques, and mitigate the neurotoxicity induced by Aβ_1-42 through ROS generation^[1].
BuChE-IN-20 (1 mM, 30 min) exerts scavenging capacities for hydroxyl radicals 775 times that of vitamin C^[1].
BuChE-IN-20 (5-10 μM, 4 h pretreatment and 8 h cotreatment with LPS) decreases intracellular reactive oxygen species (ROS) concentration-dependently in LPS (1.5 μg/mL) (HY-D1056)-induced RAW264.7 cells^[1].
BuChE-IN-20 (6.25-12.5 μM, 4 h pretreatment and 24 h cotreatment with LPS) demonstrates potent inhibitory activity on LPS (2 μg/mL)-induced NO production in RAW264.7 cells^[1].
BuChE-IN-20 (1-100 μM, 24 h) exerts inhibitory effects and free radical scavenging at sub-micromolar concentrations in mouse BV-2 cell line, with a safety margin of nearly 150-fold regarding cytotoxicity^[1].
BuChE-IN-20 (1-10 μM, 24 h pretreatment and 24 h cotreatment with LPS) decreases IL-1β levels in LPS (100 ng/mL)-induced BV-2 cells^[1].
BuChE-IN-20 (1-20 μM, 6 h pretreatment and 24 h cotreatment with NMDA/Sodium L-Glutamate) mitigates the cytotoxic effects dose-dependently in NMDA (20 mM)/Sodium L-Glutamate(Glu) (HY-N0455B)-induced SH-SY5Y cell injury model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BuChE-IN-20 (Compound 4d-13) (10-100 mg/kg, p.o., one single dose) shows no toxic or abnormal symptoms with the maximum tolerated dose of 100 mg/kg in ICR mice model^[1].
BuChE-IN-20 (10-40 mg/kg, p.o., one single dose) shows notable positive effect on improving learning and memory function in (-)-Scopolamine hydrobromide (HY-W010892) (3 mg/kg, i.p.)-induced ICR mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

484.56

C₂₉H₂₉FN₄O₂

OC1=C(F)C=C(CN[C@@H](CC2=CNC3=CC=CC=C32)C(N(C)CCC4=CNC5=C4C=CC=C5)=O)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Atlante S, et al., A Xanthine Derivative With Novel Heat Shock Protein 90-Alpha Inhibitory and Senolytic Properties. Aging Cell. 2025 Mar 17:e70047.  [Content Brief]